An evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma
Massimo Offidani,1 Laura Corvatta,2 Patrizia Caraffa,1 Silvia Gentili,1 Laura Maracci,1 Pietro Leoni1 1Hematology Department, Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona, 2Division of Medicine, Ospedale Stelluti Scala, Fabriano, Italy Abstract: Proteasome inhibition represents one...
Main Authors: | Offidani M, Corvatta L, Caraffa P, Gentili S, Maracci L, Leoni P |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2014-09-01
|
Series: | OncoTargets and Therapy |
Online Access: | http://www.dovepress.com/an-evidence-based-review-of-ixazomib-citrate-and-its-potential-in-the--peer-reviewed-article-OTT |
Similar Items
-
Spotlight on ixazomib: potential in the treatment of multiple myeloma
by: Muz B, et al.
Published: (2016-01-01) -
Ixazomib in the treatment of relapsed multiple myeloma
by: S. V. Semochkin
Published: (2018-07-01) -
T‐cell pseudolymphoma secondary to ixazomib for multiple myeloma
by: M. Haq, et al.
Published: (2021-09-01) -
Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments
by: Massimo Offidani, et al.
Published: (2021-02-01) -
Accidental Ixazomib Overdose in a Patient With Multiple Myeloma
by: Parth J. Sampat MBBS, et al.
Published: (2021-05-01)